Biograph 64 truepoint truev pet ct system

All patients underwent ⁶⁸Ga-NEB PET/CT. Preparation of NEB and ⁶⁸Ga labeling were performed as described in previous publications.^{17 (link)} A Biograph 64 True Point TrueV PET/CT system (Siemens Medical Solutions, Erlangen, Germany) was used. For the patient with upper extremity swelling, the tracer (0.5 mL, 37 MBq/hand) was injected into the subcutaneous tissue between the thumb and index finger of each hand. For other patients, ⁶⁸Ga-NEB was injected subcutaneously into the bilateral first web spaces of the feet (0.5 mL, 37 MBq/foot), followed by massage of the injection sites. The patients were requested to walk after tracer injection. For those patients with suspected chylothorax, chyloperitoneum, or chyluria, the images were acquired 5 to 20 minutes after tracer injection. For those with lymphedema, longer interval up to 1 hour between the tracer injection and image acquisition was applied. Whole-body images were acquired using a low-dose CT scan (120– kV, 35 mA, 3-mm layer, 512 × 512 matrix, 70 cm FOV). PET acquisition was performed (8–11 bed positions, 2 min/bed).

The PET data were acquired on a Biograph 64 TruePoint TrueV PET/CT system (Siemens Medical Solutions, Erlangen, Germany). FDG was produced on-site using a RDS-111 Cyclotron (CTI, Knoxville, TN, USA) and standard procedures for FDG production. Before the PET examinations, the patients were required to fast for at least 4 h; the level of blood glucose in each patient was confirmed to be within normal limits (< 6.4 mM). We administered FDG intravenously at a dose of 5.55 MBq (0.15 mCi) per kilogram of body weight.